Marshall Wace’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.27M Buy
44,600
+43,400
+3,617% +$2.02M ﹤0.01% 1715
2025
Q4
$35.4K Sell
1,200
-358,400
-100% -$9.74M ﹤0.01% 2799
2025
Q3
$9.29M Buy
+359,600
New +$10M 0.01% 938
2023
Q2
Sell
-40,600
Closed -$6.24M 2787
2023
Q1
$6.24M Sell
40,600
-99,100
-71% -$16.3M 0.01% 890
2022
Q4
$25.1M Buy
139,700
+18,600
+15% +$3.04M 0.06% 383
2022
Q3
$14.3M Buy
121,100
+11,700
+11% +$1.78M 0.03% 629
2022
Q2
$15.6M Buy
109,400
+72,900
+200% +$10.4M 0.03% 594
2022
Q1
$6.29M Buy
36,500
+34,000
+1,360% +$5.72M 0.01% 1203
2021
Q4
$634K Buy
+2,500
New +$731K ﹤0.01% 2682

Other funds holding MRNA

Marshall Wace's MRNA Position: Q1 2026 in Review

Marshall Wace increased its Moderna (MRNA) stake by 12% in Q1 2026, buying an estimated $671K and bringing the position to 133,815 shares worth $6.8M. The position accounts for 0.01% of the portfolio, ranked #1153.

Marshall Wace first reported a position in MRNA in Q2 2019 and has held it in 20 quarters since. The position peaked at $139M in Q1 2022. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Marshall Wace held 133,815 shares of Moderna worth $6.8M as of Q1 2026.
  • Marshall Wace bought 14,374 Moderna shares in Q1 2026, an estimated $671K.
  • Moderna made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1153 holding.
  • Marshall Wace first reported a position in Moderna in Q2 2019 and has held it in 20 quarters since.
  • Marshall Wace's Moderna position peaked at $139M in Q1 2022.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.